IFNG and neoplasm: Later, a phase II clinical trial using the second generation of Dex, exosomes derived from interferon (IFN)-γ-maturated DCs (IFN-γ-Dex) pulsed with tumor-associated antigenic peptides, was carried out in patients bearing advanced non-small cell lung cancer [115].